Valproic acid-mediated neuroprotection and neurogenesis after spinal cord injury: from mechanism to clinical potential

References

• 1 ISCOS. SCI Global Mapping. www.iscos.org.uk/page.php?content=67.
  Google Scholar
• 2 Rabchevsky AG, Patel SP, Springer JE. Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? Pharmacol. Ther. 132(1), 15–29 (2011).
  Medline CASGoogle Scholar
• 3 Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol. Exp. (Wars) 71(2), 281–299 (2011).
  MedlineGoogle Scholar
• 4 Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 4(4), 451–464 (2004).
  MedlineGoogle Scholar
• 5 Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat. Rev. Neurosci. 7(8), 628–643 (2006).
  Medline CASGoogle Scholar
• 6 Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu. Rev. Neurosci. 28, 223–250 (2005).
  Medline CASGoogle Scholar
• 7 Jellinger K. The Handbook of Neuroprotection. Springer, NY, USA (2011).
  Google Scholar
• 8 Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 65(1), 105–142 (2013).
  Medline CASGoogle Scholar
• 9 Chen S, Wu H, Klebe D, Hong Y, Zhang J. Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries. Neurochem. Res. 39(9), 1621–1633 (2014).
  Medline CASGoogle Scholar
• 10 Abematsu M, Tsujimura K, Yamano M et al. Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J. Clin. Invest. 120(9), 3255–3266 (2010).
  Medline CASGoogle Scholar
• 11 Lv L, Han X, Sun Y, Wang X, Dong Q. Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp. Neurol. 233(2), 783–790 (2012).
  Medline CASGoogle Scholar
• 12 Lv L, Sun Y, Han X, Xu CC, Tang YP, Dong Q. Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res. 1396, 60–68 (2011).
  Medline CASGoogle Scholar
• 13 Lee JY, Maeng S, Kang SR et al. Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome C release after spinal cord injury. J. Neurotrauma 31(6), 582–594 (2014).
  MedlineGoogle Scholar
• 14 Su Z, Niu W, Liu ML, Zou Y, Zhang CL. In vivo conversion of astrocytes to neurons in the injured adult spinal cord. Nat. Commun. 5, 3338 (2014).
  MedlineGoogle Scholar
• 15 Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl Acad. Sci. USA 101(47), 16659–16664 (2004).
  Medline CASGoogle Scholar
• 16 Laeng P, Pitts RL, Lemire AL et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 91(1), 238–251 (2004).
  Medline CASGoogle Scholar
• 17 Chen PS, Peng GS, Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11(12), 1116–1125 (2006).
  Medline CASGoogle Scholar
• 18 Hao Y, Creson T, Zhang L et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24(29), 6590–6599 (2004).
  Medline CASGoogle Scholar
• 19 Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010, pii:479364 (2010).
  MedlineGoogle Scholar
• 20 Frey HH, Loscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17(8), 637–642 (1978).
  Medline CASGoogle Scholar
• 21 Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol. Sci. 30(10), 509–514 (2009).
  Medline CASGoogle Scholar
• 22 Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg. Focus 25(5), E2 (2008).
  MedlineGoogle Scholar
• 23 Beattie MS, Farooqui AA, Bresnahan JC. Review of current evidence for apoptosis after spinal cord injury. J. Neurotrauma 17(10), 915–925 (2000).
  Medline CASGoogle Scholar
• 24 Fehlings MG, Tator CH. The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp. Neurol. 132(2), 220–228 (1995).
  Medline CASGoogle Scholar
• 25 Eidelberg E, Straehley D, Erspamer R, Watkins CJ. Relationship between residual hindlimb-assisted locomotion and surviving axons after incomplete spinal cord injuries. Exp. Neurol. 56(2), 312–322 (1977).
  Medline CASGoogle Scholar
• 26 Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32(11), 591–601 (2009).
  Medline CASGoogle Scholar
• 27 Nan G, Li M, Liao W, Qin J, Cao Y, Lu Y. Effect of valproic acid on endogenous neural stem cell proliferation in a rat model of spinal cord injury. Neural Regen. Res. 4(7), 513–517 (2009).
  CASGoogle Scholar
• 28 Penas C, Verdu E, Asensio-Pinilla E et al. Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury. Neuroscience 178, 33–44 (2011).
  Medline CASGoogle Scholar
• 29 Yu SH, Cho DC, Kim KT, Nam KH, Cho HJ, Sung JK. The neuroprotective effect of treatment of valproic acid in acute spinal cord injury. J. Korean Neurosurg. Soc. 51(4), 191–198 (2012).
  Medline CASGoogle Scholar
• 30 Lee JY, Kim HS, Choi HY, Oh TH, Ju BG, Yune TY. Valproic acid attenuates blood-spinal cord barrier disruption by inhibiting matrix metalloprotease-9 activity and improves functional recovery after spinal cord injury. J. Neurochem. 121(5), 818–829 (2012).
  Medline CASGoogle Scholar
• 31 Abdanipour A, Schluesener HJ, Tiraihi T. Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science. Iran Biomed. J. 16(2), 90–100 (2012).
  Medline CASGoogle Scholar
• 32 Hao HH, Wang L, Guo ZJ et al. Valproic acid reduces autophagy and promotes functional recovery after spinal cord injury in rats. Neurosci. Bull. 29(4), 484–492 (2013).
  Medline CASGoogle Scholar
• 33 Lu WH, Wang CY, Chen PS et al. Valproic acid attenuates microgliosis in injured spinal cord and purinergic P2X4 receptor expression in activated microglia. J. Neurosci. Res. 91(5), 694–705 (2013).
  Medline CASGoogle Scholar
• 34 Bang WS, Kim KT, Cho DC, Kim HJ, Sung JK. Valproic Acid increases expression of neuronal stem/progenitor cell in spinal cord injury. J. Korean Neurosurg. Soc. 54(1), 8–13 (2013).
  Medline CASGoogle Scholar
• 35 Go HS, Seo JE, Kim KC et al. Valproic acid inhibits neural progenitor cell death by activation of NF-kappaB signaling pathway and up-regulation of Bcl-XL. J. Biomed. Sci. 18(1), 48 (2011).
  Medline CASGoogle Scholar
• 36 Kanno H, Ozawa H, Sekiguchi A, Yamaya S, Itoi E. Induction of autophagy and autophagic cell death in damaged neural tissue after acute spinal cord injury in mice. Spine (Phila Pa 1976) 36(22), E1427–E1434 (2011).
  MedlineGoogle Scholar
• 37 Kanno H, Ozawa H, Sekiguchi A, Itoi E. The role of autophagy in spinal cord injury. Autophagy 5(3), 390–392 (2009).
  Medline CASGoogle Scholar
• 38 Walker CL, Walker MJ, Liu NK et al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS ONE 7(1), e30012 (2012).
  Medline CASGoogle Scholar
• 39 Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 22(17), 7526–7535 (2002).
  Medline CASGoogle Scholar
• 40 Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp. Neurol. 209(2), 378–388 (2008).
  Medline CASGoogle Scholar
• 41 Schwab JM, Guo L, Schluesener HJ. Spinal cord injury induces early and persistent lesional P2X4 receptor expression. J. Neuroimmunol. 163(1–2), 185–189 (2005).
  Medline CASGoogle Scholar
• 42 Chen PS, Wang CC, Bortner CD et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149(1), 203–212 (2007).
  Medline CASGoogle Scholar
• 43 Peng GS, Li G, Tzeng NS et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134(1), 162–169 (2005).
  Medline CASGoogle Scholar
• 44 Lu J, Frerich JM, Turtzo LC et al. Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proc. Natl Acad. Sci. USA 110(26), 10747–10752 (2013).
  Medline CASGoogle Scholar
• 45 Kostrouchova M, Kostrouch Z, Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. (Praha) 53(2), 37–49 (2007).
  Medline CASGoogle Scholar
• 46 Neri LM, Borgatti P, Capitani S, Martelli AM. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim. Biophys. Acta 1584(2–3), 73–80 (2002).
  Medline CASGoogle Scholar
• 47 Van Den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37(6), 375–536 (2002).
  Medline CASGoogle Scholar
• 48 Marinova Z, Ren M, Wendland JR et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J. Neurochem. 111(4), 976–987 (2009).
  Medline CASGoogle Scholar
• 49 Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8(1), 57–69 (2007).
  Medline CASGoogle Scholar
• 50 Colton CA, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223(2), 284–288 (1987).
  Medline CASGoogle Scholar
• 51 Moss DW, Bates TE. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci. 13(3), 529–538 (2001).
  Medline CASGoogle Scholar
• 52 Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 491(2), 394–397 (1989).
  Medline CASGoogle Scholar
• 53 Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4(2), 137–144 (2002).
  Medline CASGoogle Scholar
• 54 Cuzzocrea S, Genovese T, Mazzon E et al. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther. 318(1), 79–89 (2006).
  Medline CASGoogle Scholar
• 55 Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28(10), 2576–2588 (2008).
  Medline CASGoogle Scholar
• 56 Yu IT, Park JY, Kim SH, Lee JS, Kim YS, Son H. Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. Neuropharmacology 56(2), 473–480 (2009).
  Medline CASGoogle Scholar
• 57 Jung GA, Yoon JY, Moon BS et al. Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol. 9, 66 (2008).
  MedlineGoogle Scholar
• 58 Sandner B, Prang P, Rivera FJ, Aigner L, Blesch A, Weidner N. Neural stem cells for spinal cord repair. Cell Tissue Res. 349(1), 349–362 (2012).
  MedlineGoogle Scholar
• 59 Cao QL, Howard RM, Dennison JB, Whittemore SR. Differentiation of engrafted neuronal-restricted precursor cells is inhibited in the traumatically injured spinal cord. Exp. Neurol. 177(2), 349–359 (2002).
  Medline CASGoogle Scholar
• 60 Abematsu M, Smith I, Nakashima K. Mechanisms of neural stem cell fate determination: extracellular cues and intracellular programs. Curr. Stem. Cell Res. Ther. 1(2), 267–277 (2006).
  Medline CASGoogle Scholar
• 61 Shein NA, Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol. Med. 17(5–6), 448–456 (2011).
  Medline CASGoogle Scholar
• 62 Gaub P, Tedeschi A, Puttagunta R, Nguyen T, Schmandke A, Di Giovanni S. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation. Cell Death Differ. 17(9), 1392–1408 (2010).
  Medline CASGoogle Scholar
• 63 Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276(34), 31674–31683 (2001).
  Medline CASGoogle Scholar
• 64 Marmigere F, Carroll P. Neurotrophin signalling and transcription programmes interactions in the development of somatosensory neurons. Handb. Exp. Pharmacol. 220, 329–353 (2014).
  Medline CASGoogle Scholar
• 65 Deinhardt K, Chao MV. Trk receptors. Handb. Exp. Pharmacol. 220, 103–119 (2014).
  Medline CASGoogle Scholar
• 66 Takahashi-Yanaga F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J. Pharmacol. Sci. 104(4), 293–302 (2007).
  Medline CASGoogle Scholar
• 67 Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29(2), 95–102 (2004).
  Medline CASGoogle Scholar
• 68 Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin – developmental effects of valproic acid. Crit. Rev. Toxicol. 35(8–9), 727–738 (2005).
  Medline CASGoogle Scholar
• 69 Sinha D, Wang Z, Ruchalski KL et al. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am. J. Physiol. Renal Physiol. 288(4), F703–F713 (2005).
  Medline CASGoogle Scholar
• 70 Kuwabara T, Hsieh J, Muotri A et al. Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nat. Neurosci. 12(9), 1097–1105 (2009).
  Medline CASGoogle Scholar
• 71 Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci. 6(5), 351–362 (2005).
  Medline CASGoogle Scholar
• 72 Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS‐‐fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol. Neurobiol. 36(3), 245–253 (2007).
  Medline CASGoogle Scholar
• 73 Dietrich WD. Confirming an experimental therapy prior to transfer to humans: what is the ideal? J. Rehabil Res. Dev. 40(4 Suppl. 1), 63–69 (2003).
  MedlineGoogle Scholar
• 74 Holtz. A, Levi. R. Epidemiology. Spinal Cord Injury 2, 9–11 (2010).
  Google Scholar
• 75 Obalum DC, Giwa SO, Adekoya-Cole TO, Enweluzo GO. Profile of spinal injuries in Lagos, Nigeria. Spinal Cord. 47(2), 134–137 (2009).
  Medline CASGoogle Scholar
• 76 Levi AD, Dancausse H, Li X, Duncan S, Horkey L, Oliviera M. Peripheral nerve grafts promoting central nervous system regeneration after spinal cord injury in the primate. J. Neurosurg. 96(Suppl. 2), 197–205 (2002).
  MedlineGoogle Scholar
• 77 Houle JD, Ye JH. Changes occur in the ability to promote axonal regeneration as the post-injury period increases. Neuroreport 8(3), 751–755 (1997).
  Medline CASGoogle Scholar
• 78 Steeves JD, Lammertse D, Curt A et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45(3), 206–221 (2007).
  Medline CASGoogle Scholar
• 79 Lammertse D, Tuszynski MH, Steeves JD et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 45(3), 232–242 (2007).
  Medline CASGoogle Scholar
• 80 Tuszynski MH, Steeves JD, Fawcett JW et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 45(3), 222–231 (2007).
  Medline CASGoogle Scholar
• 81 Fawcett JW, Curt A, Steeves JD et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 45(3), 190–205 (2007).
  Medline CASGoogle Scholar